Abstract:Xiao-Bei Si, 1, 2 Ling-Yun Zhang, 2 Shuo Yang, 3 Xiao-Lu Chen, 2 Yan-Yan Shi, 4 Yu Lan, 2 Shi-Gang Ding 1 1 Department of Gastroenterology, Peking University Third Hospital, Beijing, People's Republic of China; 2 Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China; 3 Department of Pharmacy, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China; 4 Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, People's Republic of China Correspondence: Shi-Gang Ding, Department of Gastroenterology, Peking University Third Hospital, Beijing, People's Republic of China, Email Yu Lan, Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, People's Republic of China, Email Background: Minocycline, a derivative of tetracycline, has anti- Helicobacter pylori ( H. pylori ) properties and can be used to treat H. pylori infection. However, only a few randomized controlled trials (RCTs) have investigated the efficacy of minocycline-containing quadruple therapy (MCQT) in treating H. pylori infection. This study aimed to determine the efficacy and safety of MCQT and investigate the factors influencing both aspects. Methods: This was a retrospective cohort study. Patients diagnosed with H. pylori infection between January 1, 2022, and July 31, 2023 at. The primary outcome was the eradication rate of H. pylori , and the secondary outcome was the number and type of adverse events. Results: A total of 828 patients were included in this study. The overall H. pylori eradication rate among the included patients at 95% confidence interval (CI) (Range 0.864 to 0.907) was 88.53%. The H. pylori eradication rate for patients who received MCQT regimen as the primary therapy was 92.28% (95% CI: 0.901– 0.945), significantly higher than that of patients who received MCQT as rescue therapy (80.81%; 95% CI: 0.761– 0.855, P= 0.003). Adverse events, including dizziness, abdominal distension, diarrhea, nausea, abdominal discomfort, constipation, headache, rash, sleep disorder, palpitation, backache, and anorexia, occurred in 185 (22.34%) patients, with dizziness being the most common (75/828, 9.06%). Compliance with MCQT therapy was an independent factor influencing H. pylori eradication in patients receiving MCQT as a primary therapy. Compliance and presence or absence of H. pylori infection symptoms at the time of screening were independent factors influencing H. Pylori eradication in patients receiving MCQT as rescue therapy. Factors that influenced the occurrence of adverse events included reasons for H. pylori infection screening, residence, treatment compliance, and the use of acid-suppressant regimens. Conclusion: MCQT regimens were effective in H. pylori infection eradication, and the treatment resulted only in fewer adverse events when used as primary or rescue therapies for H. pylori infection treatment. Future prospective studies with larger sample sizes and more comprehensive data are needed to validate our findings. Keywords: Helicobacter pylori , minocycline, cohort study Helicobacter pylori ( H. pylori ) is a gram-negative, microaerophilic bacterium that colonizes human gastric mucosa. 1 H. pylori causes many diseases, including chronic gastritis, gastric and duodenal ulcers, mucosa-associated lymphoid tissue development, and gastric adenocarcinoma. 2 Currently, triple therapy (proton-pump inhibitor combined with two antibiotics) and bismuth quadruple therapy (proton-pump inhibitor, bismuth, and two antibiotics) are used globally to treat H. pylori infection. 3 China is one of the countries with the highest clarithromycin resistance rates in the world. 4 Accordingly, bismuth quadruple therapy has been recommended over triple therapy for initial and second-line H. pylori treatment. However, triple therapy is the currently recommended treatment for H. pylori . 4 Several studies have shown that the efficacy of BCQT against H. pylori infection has gradually decreased 3 in past decades, with antibiotic resistance implicated as one of the main resources. 5 In 2022, Chinese national clinical practice guideline 4 on H. pylori treatment recommended high-dose dual therapy (HDDT), a new, improved therapy consisting of amoxicillin (≥3.0 g/day) and PPIs (double dose twice per day o -Abstract Truncated-

Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Pilot Study

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Application of Minocycline-Containing Bismuth Quadruple Therapies As First-Line Regimens in the Treatment of Helicobacter Pylori.

Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial

Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study

Ten-Day Bismuth-Containing Quadruple Therapy is Effective As First-Line Therapy for Helicobacter Pylori-Related Chronic Gastritis: A Prospective Randomized Study in China

Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial

The Efficacy and Safety of Minocycline‐Containing Quadruple Therapies Against Helicobacter pylori Infection: A Retrospective Cohort Study

Efficacy and Safety of Bismuth Quadruple Regimens Containing Minocycline and Vonoprazan for Eradication of Helicobacter Pylori: Real‐world Evidence

Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy

Efficacy and safety of low-dose tetracycline, amoxicillin quadruple therapy in Helicobacter pylori infection: A retrospective single center study

Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial

Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy

Evaluation of Bismuth-clarithromycin-containing Quadruple Therapy for Initial Helicobacter pylori Eradication

Antofloxacin-based Bismuth Quadruple Therapy is Safe and Effective in Helicobacter Pylori Eradication: A Prospective, Open-Label, Randomized Trial

Bismuth, Rabeprazole, Amoxicillin, and Doxycycline As First-Line Helicobacter Pylori Therapy in Clinical Practice: A Pilot Study.

Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.

Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China